• Explore /
  • Poster
  • / The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES).

The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES).

Abstract Poster

Authors

null

Paul A. Meyers

Memorial Sloan Kettering Cancer Center, New York, NY

Paul A. Meyers , Srikanth R. Ambati , Emily Kanaya Slotkin , Filemon Dela Cruz , Leonard H. Wexler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT01864109

Citation

J Clin Oncol 36, 2018 (suppl; abstr 10533)

DOI

10.1200/JCO.2018.36.15_suppl.10533

Abstract #

10533

Poster Bd #

206

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.

Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.

First Author: Michael W. Bishop

First Author: Danielle Klingberg

First Author: Cynthia Wei

First Author: Heather D. Magnan